ClinicalTrials.gg
CompletedNCT02245620MOTIONUpdated Jun 23, 2020Results posted

A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly

A Phase 2 interventional study of Elamipretide and Placebo in Skeletal Muscle Mitochondrial Dysfunction in the Elderly, sponsored by Stealth BioTherapeutics Inc.. Completed at 1 site in United States. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-06-23.

Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Mitochondrial Diseases with a site in United States — 20 open to participants now, 22 under way, 3 of them phase 3. Mitochondrial Diseases · United States.

Enrollment
23rd of 50
41 · median 38
Started
2015
with 3 others
Phase 2
16 of 83
1 open now
Registered
36th of 83
by date
Lead sponsor
3 of 83
Stealth BioTherapeutics Inc.

Among the 83 studies in Mitochondrial Diseases with a site in United States, this one is the 23rd largest by enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2015, is one of 16 in phase 2, and was the 36th registered.

Mitochondrial Diseases

189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.

Browse Mitochondrial Diseases studies →

Open to participants now

20 of the 83 studies in Mitochondrial Diseases with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Mitochondrial Diseases studies recruiting now, 20 (49%) set no upper age limit and 14 (34%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Mitochondrial Diseases with a site in United States, or all of them as a file.
02

Study summary

This was a Phase 2, randomized, double-blind, placebo-controlled study, enrolling 41 elderly subjects with previous evidence of mitochondrial dysfunction to evaluate whether the administration of MTP-131 (elamipretide) will change either hand skeletal muscle energetics or muscle performance in age-related skeletal muscle mitochondrial dysfunction.

Read the detailed description

This was a Phase 2, randomized, double-blind, placebo-controlled study, enrolling 41 elderly subjects with previous evidence of mitochondrial dysfunction to evaluate whether the administration of MTP-131 (elamipretide) will change either hand skeletal muscle energetics or muscle performance in age-related skeletal muscle mitochondrial dysfunction.

Subjects were randomized 1:1 to receive either elamipretide at 0.25 mg/kg/hr intravenously at a rate of 60 mL/hr for 2 hours, or placebo (lyophilized excipients without elamipretide) intravenously at a rate of 60 mL/hr for 2 hours. Each treatment group went through three distinct periods: Screening (up to 28 days), Treatment (1day), and Observation (7 days).

03

Conditions studied

  • Skeletal Muscle Mitochondrial Dysfunction in the Elderly

Keywords

  • Skeletal muscle dysfunction, MTP-131, Bendavia™
  • elamipretide
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are male and female adults aged ≥60 and ≤85 years
  2. Female subjects must be
  3. Have in vivo phosphorus-31 (31P) Magnetic Resonance Spectroscopy (MRS) and (Optical Spectra Scan (OPS) determined maximum adenosine triphosphate synthetic rate (ATPmax) \< 0.70 milliMol/second (mM/sec)
  4. Have in vivo 31P MRS and OPS determined P/O (Phosphate/Oxygen ratio) \< 1.9
  5. Are ambulatory and able to perform activities of daily living without assistance
  6. Had sufficient venous access for study drug administration and clinical testing.
  7. Could speak and read English fluently.
  8. Provided .

Exclusion criteria

Exclusion Criteria:

  1. Had significant disease(s) or condition(s) which, in the opinion of the Investigator, may have put the subject at risk because of their participation in the study or may have influenced either the results of the study or the subject's ability to participate in the study.
  2. Had a history of rhabdomyolysis.
  3. Had been hospitalized within 3 months prior to Screening for major atherosclerotic events (e.g., myocardial infarction, target-vessel revascularization, coronary bypass surgery or stroke) or other major medical condition (as deemed by the Primary Investigator).
  4. Had any metal implants that could not be removed from the body that in the opinion of the Investigator were a for undergoing the MRS procedure or any other protocol-related procedure.
  5. Had an implanted cardiac pacemaker or other implanted cardiac device.
  6. Had a serum sodium level \<136 milliequivalents per litre (mEq/L) at Screening or Pre-infusion.
  7. Had a level \<12 g/dL at Screening or Pre-infusion.
  8. Had chronic, uncontrolled hypertension as judged by the Investigator (e.g., Baseline systolic blood pressure [SBP] >140 mm Hg, diastolic blood pressure [DBP] > 90 mm Hg) or a SBP >150 mm Hg or DBP >95 mm Hg at the time of Screening or Baseline (if the initial blood pressure [BP] reading was above these values, the reading may have been repeated one time within 20 minutes of the initial reading).
  9. Had a (BMI) of \<16 or >35 kg/m2.
  10. Had a \<45 mL/min as calculated by the Cockcroft Gault equation.
  11. Had a 12-lead (ECG) demonstrating severe bradycardia (heart rate \< 40 bpm) or average corrected QC interval () >450 ms for males and > 470 ms for females, and in the opinion of the Investigator was . (If on the initial ECG, QTc exceeded 450 ms for males or 470 ms for females, the ECG was to be repeated 2 more times and the average of the 3 QTc values was to be used to determine the subject's eligibility).
  12. Had a neurologic disorder that in the opinion of the Investigator was a contra-indication for enrollment into the study.
  13. Had any symptoms consistent with or a current diagnosis of peripheral neuropathy, such as numbness, tingling, pain, or altered sensation of hands or feet.
  14. Had an active, systemic disease other than autoimmune thyroid disease (e.g., diabetes, lupus, rheumatoid arthritis) that currently required treatment or was likely to require treatment during the study.
  15. Subject's right hand had a history of mobility impairment, fractures, arthritis, hand surgery, muscle disease or other injury that may interfere with any study procedure.
  16. Had any symptoms consistent with or a current diagnosis of claustrophobia.
  17. Had a history of cancer, unless subject had documentation of completed curative treatment.
  18. Had a history of or risk factors (e.g., significant family history, concomitant medical condition) for deep vein thrombosis or pulmonary embolism.
  19. Had a history of serious mental illness as judged by the Investigator.
  20. Had a body temperature > 37.5°C at the time of planned dosing.
  21. Subjects who in the opinion of the Investigator abused alcohol or drugs.
  22. Had donated or received blood or blood products within the past 30 days.
  23. Investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family was defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
  24. Sponsor employees and/or their immediate families. Immediate family was defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
  25. Were currently enrolled in a clinical study involving an product or non-approved use of a drug or device or concurrently enrolled in any other type of medical research judged to be scientifically or medically incompatible with this study.
  26. Had participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product had a long half-life, 3 months or 5 half-lives (whichever was longer) should have passed.
  27. Had previously been randomized into any study investigating elamipretide or been exposed to elamipretide for any reason.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Elamipretide

    Elamipretide given as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.

    Drug: Elamipretide

  • Placebo comparator
    Placebo

    Placebo (lyophilized excipients without elamipretide) given as an intravenous infusion at a rate of 60 mL/hr for 2 hours.

    Drug: Placebo

Interventions

  • Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours

    Also known as: MTP-131, Bendavia™

  • DrugPlacebo

    Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours

    Also known as: elamipretide

06

What researchers measure

Primary outcomes

  1. Change From Baseline in ATPmax (Maximal ATP Synthetic Rate)

    Maximal ATP synthetic rate (phosphorylation capacity per unit muscle volume) as determined by a muscle fatigue test.

    Time frame: From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7

Secondary outcomes

  1. Mean Change From Baseline in Phosphate/Oxygen (P/O) Ratio

    As a measure of mitochondrial hand skeletal muscle energetics, mitochondrial coupling, or Phosphate/Oxygen ratio (P/O) was assessed at Baseline, Day 1 Hour 2, and Day 7.

    Time frame: From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7

  2. Mean Change From Baseline in Nicotine Adenine Dinucleotide (NAD)

    Time frame: From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7

  3. Mean Change From Baseline in Muscle Force-Time-Integral (FTI)

    Muscle Force-Time-Integral was measured as mean change from baseline at Day 1 Hour 2, Day 3, and Day 7.

    Time frame: From Baseline to Day 1 Hour 2, Day 3, and Day 7

07

Results

Posted Jun 23, 2020

Participant flow

Participant flow — Overall Study
MilestoneElamipretidePlacebo
Started2021
Completed1920
Not completed11
Withdrew: Physician decision11

Outcome measures

PrimaryChange From Baseline in ATPmax (Maximal ATP Synthetic Rate)

Maximal ATP synthetic rate (phosphorylation capacity per unit muscle volume) as determined by a muscle fatigue test.

Time frame:
From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7
Reported as:
Mean · mM/sec
Change From Baseline in ATPmax (Maximal ATP Synthetic Rate)
mM/secMTP-131 (Bendavia™)Placebo
Day 1 Hour 20.17 ± 0.1960.12 ± 0.244
Day 70.09 ± 0.1420.06 ± 0.172
SecondaryMean Change From Baseline in Phosphate/Oxygen (P/O) Ratio

As a measure of mitochondrial hand skeletal muscle energetics, mitochondrial coupling, or Phosphate/Oxygen ratio (P/O) was assessed at Baseline, Day 1 Hour 2, and Day 7.

Time frame:
From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7
Reported as:
Mean · ratio of phosphate to oxygen
Mean Change From Baseline in Phosphate/Oxygen (P/O) Ratio
ratio of phosphate to oxygenMTP-131 (Bendavia™)Placebo
Day 1 Hour 20.25 ± 0.6790.26 ± 0.693
Day 70.32 ± 0.4730.51 ± 0.788
SecondaryMean Change From Baseline in Nicotine Adenine Dinucleotide (NAD)
Time frame:
From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7
Reported as:
Mean · millimolar
Mean Change From Baseline in Nicotine Adenine Dinucleotide (NAD)
millimolarMTP-131 (Bendavia™)Placebo
Day 1 Hour 20.04 ± 0.1690.01 ± 0.213
Day 70.11 ± 0.2150.09 ± 0.263
SecondaryMean Change From Baseline in Muscle Force-Time-Integral (FTI)

Muscle Force-Time-Integral was measured as mean change from baseline at Day 1 Hour 2, Day 3, and Day 7.

Time frame:
From Baseline to Day 1 Hour 2, Day 3, and Day 7
Reported as:
Mean · Newton/second
Mean Change From Baseline in Muscle Force-Time-Integral (FTI)
Newton/secondMTP-131 (Bendavia™)Placebo
Day 1 Hour 20.43 ± 0.8820.10 ± 0.728
Day 30.46 ± 1.0360.24 ± 0.948
Day 70.83 ± 1.4850.44 ± 1.114

Adverse events

Collected over 36 days. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elamipretide0/19 (0%)0/19 (0%)3/19 (15.8%)
Placebo0/20 (0%)0/20 (0%)2/20 (10%)
Most frequent other events
Most frequent other events
EventElamipretidePlacebo
DizzinessNervous system disorders1/190/20
PalpitationsCardiac disorders1/190/20
Herpes zosterInfections and infestations1/190/20
Sinus congestionRespiratory, thoracic and mediastinal disorders1/190/20
HeadacheNervous system disorders0/191/20
NauseaGastrointestinal disorders0/191/20
Vessel puncture site bruiseGeneral disorders0/191/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)MTP-131 (Bendavia™)PlaceboTotal
Mean67.9 ± 3.3569.0 ± 3.9668.5 ± 3.67
Sex: Female, Male
Sex: Female, Male(Participants)MTP-131 (Bendavia™)PlaceboTotal
Female11718
Male81321
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MTP-131 (Bendavia™)PlaceboTotal
Hispanic or Latino101
Not Hispanic or Latino181937
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MTP-131 (Bendavia™)PlaceboTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White182038
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)MTP-131 (Bendavia™)PlaceboTotal
United States192039
Body Mass index
Body Mass index(kg/m²)MTP-131 (Bendavia™)PlaceboTotal
Mean26.5 ± 4.2726.1 ± 2.8226.3 ± 3.56
08

Study locations

1 site
  • The University of Washington Medical Center
    Seattle, Washington 98104, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Jul 2016, 17 months.

Results were first posted in Jun 2020, 3 years 11 months after primary completion.

Of 16 phase 2 interventional studies under Mitochondrial Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 85. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2014
First posted
Sep 19, 2014
StartActual
Jan 15, 2015
Primary completionActual
Jul 6, 2016
CompletionActual
Jul 6, 2016
Results first posted
Jun 23, 2020
Last update
Jun 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02245620
Responsible party
Sponsor
First posted
Sep 19, 2014
Start date
Jan 15, 2015
Primary completion
Jul 6, 2016
Completion
Jul 6, 2016
Results posted
Jun 23, 2020
Last update
Jun 23, 2020

Study contacts

Jim Carr
study director · Stealth BioTherapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion